Helen M. Thackray - 19 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief R&D Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 19 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 21 Dec 2022, 15:41:02 UTC
Previous filing: 19 Dec 2022
Next filing: 04 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+81,000	+61%	$0.000000	214,275	19 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+238,000		$0.000000	238,000	19 Dec 2022	Common Stock	238,000	$10.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.